|Videos|August 3, 2021

Complementary use of mpMRI and genomic testing in prostate cancer

Author(s)Urology Times staff

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Mary Dunn, MSN, RN, NP-C, OCN, on the role of APPs in genetic testing

ByMary Dunn, MSN, RN, NP-C, OCN

August 29th 2026

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice

ByJoshua Lang, MD, MS

July 31st 2026

Genomic Prostate Score may help refine risk assessment in localized prostate cancer

ByHannah Clarke

July 14th 2026

Prolaris CCR score demonstrates prognostic value in localized prostate cancer

ByHannah Clarke

July 7th 2026

Workflow, staffing are key to genetic testing in safety-net systems

ByKalyani Narra, MD

March 10th 2026

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

AI-generated profiles impersonate female urologists to market ED products online

Alternative BCG strains may help address ongoing supply challenges in NMIBC

Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA

Doublet or triplet? Urologists weighs in on mCSPC options

Prior auth, step therapy, and consolidation pressure: Independent urology's challenge